Skip Navigation



European Heart Journal Advance Access published online on June 13, 2008
European Heart Journal, doi:10.1093/eurheartj/ehn255
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
29/14/1709    most recent
ehn255v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kintscher, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kintscher, U.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS

Ulrich Kintscher*

Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charité-Universitätsmedizin Berlin, Hessische Str. 3–4, D-10115 Berlin, Germany

* Corresponding author. Tel: +49 30450525276, Fax: +49 30450525901, Email: ulrich.kintscher@charite.de

This editorial refers to ‘Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: 2-year results from the RIO-Europe Study’, by L.F. Van Gaal et al. doi:10.1093/eurheartj/ehn076

The first 10% of the full text of this article appears below.

The prevalence of obesity and associated metabolic/cardiovascular disease has reached epidemic proportions in industrialized and developing countries. Dietary and behavioural approaches are insufficient to maintain weight loss and to fight this trend. Therefore, effective and safe new pharmacological therapies are absolutely required to overcome this obesity burden. One promising new strategy is the blockade of the endocannabinoid system which is involved in the regulation of energy balance, food intake, and lipid/glucose metabolism.1

Rimonabant is a first-in-class, selective cannabinoid receptor type 1 (CB1 receptor) antagonist, which has been shown to reduce body weight consistently in obese and overweight individuals.2–5 Data from the Rimonabant in Obesity (RIO) trial programme revealed that 1-year therapy with rimonabant results in a 4.7 kg greater mean weight loss than placebo.6 In addition, rimonabant treatment . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study
Luc F. Van Gaal, André J. Scheen, Aila M. Rissanen, Stephan Rössner, Corinne Hanotin, Olivier Ziegler, and for the RIO-Europe Study Group
EHJ 2008 29: 1761-1771. [Abstract] [FREE Full Text]